title: Clinical and electrophysiological evaluation of patients with thalidomide-induced neuropathy.
abstract: BACKGROUND
  Whether thalidomide induces a sensory ganglionopathy or a length-dependent axonal neuropathy is disputed. Moreover no agreement exists concerning the effects of thalidomide dosage on the clinical and electrophysiological findings.
  
  
  OBJECTIVE
  We examined the effect of age, gender disease duration, total cumulative dose on the clinical and electrophysiologic parameters.
  
  
  METHODS
  Fifteen patients who had previously received 100 mg/day of thalidomide for the treatment of multiple myeloma were evaluated retrospectively. Clinical findings and nerve conductions studies were evaluated using a modified total neuropathy scoring system.
  
  
  RESULTS
  Sensory symptoms (p = 0.033, r = 0.552) and objective sensory findings (p = 0.002, r = 0.730) worsened with higher thalidomide doses. There was no effect of age, gender and disease duration, neither on clinical symptoms and objective findings, nor on electrophysiologic data. Twelve patients (80%) developed the electrophysiological findings of neuropathy. Six (40%) had pure sensory and 4 (26.6%) had sensori-motor peripheral neuropathy, while 4 (26.6%) had carpal tunnel syndrome. Sural sensory nerve action potential (SNAP) amplitudes were more prominently reduced compared to SNAPs obtained from the upper extremities. Sural SNAP amplitude showed a tendency toward reduction as the total cumulative dose, although it is not statistically significant (respectively; p = 0.187). Significantly reduced ulnar peroneal and tibial compound muscle action potential amplitudes, slow motor nerve conduction velocities of the ulnar and peroneal nerves were found in the study group compared to reference norms (p < 0.05).
  
  
  CONCLUSIONS
  Our results suggest that thalidomide produces a dose dependent peripheral neuropathy, mainly localized to the peripheral nerves in a length dependent manner. The patient must be monitored closely to prevent irreversible consequences.
authors.affiliation: Department of Neurology, Gazi University School of Medicine, Ankara, Turkey. ebkocer@yahoo.com
authors.forename: B
authors.initials: B
authors.lastname: Kocer
authors.forename: G
authors.initials: G
authors.lastname: Sucak
authors.forename: R
authors.initials: R
authors.lastname: Kuruoglu
authors.forename: Z
authors.initials: Z
authors.lastname: Aki
authors.forename: R
authors.initials: R
authors.lastname: Haznedar
authors.forename: N Ince
authors.initials: NI
authors.lastname: Erdogmus
mesh_terms: D000200:Action Potentials / Q000187:drug effects; D000293:Adolescent; D000328:Adult; D000368:Aged; D004576:Electromyography; D004594:Electrophysiology / Q000379:methods*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy; D009431:Neural Conduction / Q000187:drug effects; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced*; D013223:Statistics as Topic; D013792:Thalidomide / Q000009:adverse effects* / Q000494:pharmacology; D055815:Young Adult
chemical_list: D007166:Immunosuppressive Agents; D013792:Thalidomide